CARLSBAD, Calif., June 29, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has
been added to the Russell 1000 Index, effective June 26, 2015. The Russell 1000 Index measures
the performance of the large-cap segment of the U.S. equity
universe. It is a subset of the Russell 3000 Index and includes
approximately 1000 of the largest securities based on a combination
of their market cap and current index membership.
"We are pleased to be added to this important index, which helps
to raise awareness of our company even more broadly among
investors," said B. Lynne Parshall,
chief operating officer at Isis Pharmaceuticals. "Our
promotion to the Russell 1000 index is a reflection of the
substantial growth in Isis' valuation, the positive results
achieved with our pipeline of antisense drugs and the success of
our business strategy."
Russell Indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. The Russell 1000 Index is constructed
to provide a comprehensive and unbiased barometer for the large-cap
segment. The Russell 1000 represents approximately 92% of the U.S.
market. All Russell indices are reconstituted on an annual basis to
ensure new and growing equities are reflected accurately in each
index.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in RNA-targeted
technology to discover and develop novel drugs for its product
pipeline and for its partners. Isis' broad pipeline consists
of 38 drugs to treat a wide variety of diseases with an emphasis on
cardiovascular, metabolic, severe and rare diseases, including
neurological disorders, and cancer. Isis' partner, Genzyme,
is commercializing Isis' lead product, KYNAMRO®, in
the United States and other
countries for the treatment of patients with homozygous FH.
Isis has numerous drugs in Phase 3 development in severe/rare
diseases and cardiovascular diseases. These include
volanesorsen, a drug Isis is developing and plans to commercialize
through its wholly owned subsidiary, Akcea Therapeutics, to treat
patients with familial chylomicronemia syndrome and familial
partial lipodystrophy; ISIS-TTRRx, a drug Isis is
developing with GSK to treat patients with the polyneuropathy and
cardiomyopathy forms of TTR amyloidosis; and ISIS-SMNRx,
a drug Isis is developing with Biogen to treat infants and children
with spinal muscular atrophy, a severe and rare neuromuscular
disease. Isis' patents provide strong and extensive
protection for its drugs and technology. Additional
information about Isis is available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding
Isis Pharmaceuticals' financial position and outlook, Isis'
business, and the therapeutic and commercial potential of Isis'
technologies and products, including KYNAMRO, volanesorsen,
ISIS-SMNRx and ISIS-TTRRx, in development.
Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs is a forward-looking
statement and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. Isis' forward-looking statements
also involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements.
Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Isis. As a result, you
are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2014, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Isis Pharmaceuticals, Inc. KYNAMRO® is a
registered trademark of Genzyme Corporation.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-promoted-to-the-large-cap-russell-1000-index-300106280.html
SOURCE Isis Pharmaceuticals, Inc.